Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial | |
Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun | |
2016 | |
卷号 | 17期号:5页码:577-589 |
ISSN号 | 1470-2045 |
DOI | 10.1016/S1470-2045(16)30033-X |
URL标识 | 查看原文 |
收录类别 | SCIE ; PUBMED ; ESI高被引论文 ; ESI热点论文 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6383111 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Park, Keunchil,Tan, Eng-Huat,O'Byrne, Ken,et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J],2016,17(5):577-589. |
APA | Park, Keunchil.,Tan, Eng-Huat.,O'Byrne, Ken.,Zhang, Li.,Boyer, Michael.,...&Paz-Ares, Luis.(2016).Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.,17(5),577-589. |
MLA | Park, Keunchil,et al."Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial".17.5(2016):577-589. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论